Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 7Phase 3 2Phase 1/2 2Phase NA 1

Status

Completed 44Unknown 12Terminated 9Active not recruiting 6Withdrawn 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 2Neoplasm Metastasis 1

Interventions

Cisplatin 22Carboplatin 15Radiotherapy 13Paclitaxel 11Gemcitabine 10Rituximab 9Fluorouracil 9Drug Therapy 6Dexamethasone 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5Vinorelbine 4Pemetrexed 4Nivolumab 4Methotrexate 4Etoposide 4Docetaxel 4Bendamustine Hydrochloride 4spartalizumab 3pertuzumab 3pembrolizumab 3fludarabine 3Vincristine 3Trastuzumab 3Surgical Procedures, Operative 3Standard of Care 3Prednisone 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Sorafenib × Clear all
NCT04465734 2022-05-05

A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC

Shanghai Henlius Biotech

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT01245582 2011-11-09

SECOX

Sanofi

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡